ASG Webinar Series
Session 2: Sarcopenia, Malnutrition in IBD and Cirrhosis of the Liver
Tuesday, September 10, 2024 at 5:30 pm
Join us for an interactive session where members can inquire about sarcopenia in liver disease and inflammatory bowel disease (IBD), get insights on current evidence-based recommendations, best practices for patient management, and engage in live Q&A throughout the presentation.
Presenter:
Dr. Maitrey Raman, Physician Nutrition Specialist, Medical Educator and Clinical Associate Professor, University of Calgary
and
Dr. Puneeta Tandon, Hepatologist and founder of the Cirrhosis Care Clinic at the University of Alberta Hospital
Moderator:
Dr. Jesse Siffledeen
President of the ASG
Learning Objectives:
- Explain the pathophysiology of sarcopenia in liver disease, including the impact of cirrhosis on muscle wasting and its association with malnutrition.
- Describe the relationship between malnutrition and inflammatory bowel disease (IBD).
- Evaluate evidence-based strategies for the management of sarcopenia, malnutrition in IBD, and cirrhosis of the liver, focusing on interventions aimed at optimizing nutritional status and preserving muscle mass.
Session 3: EtOH Cessation - counselling, pharmcological, success rate
Tuesday, September 10, 2024 at 5:30 pm
Presenter:
Dr. Monty Ghosh
Dr. Monty Ghosh is an Internist and Addiction Specialist who is actively involved in research and program development in Edmonton and Calgary. He holds positions as an assistant clinical professor at both the University of Calgary and the University of Alberta. Dr. Ghosh collaborates with numerous community-based not-for-profit organizations, focusing on providing support to marginalized populations, particularly those dealing with substance use disorders, homelessness, and other vulnerabilities
Dr. Ghosh has also made significant contributions to developing innovative programs aimed at aiding individuals struggling with these issues. He holds a Master's in Public Health from Harvard, where he delivered the graduation speech for all grad students in 2022
Moderator:
Dr. Karen Kroeker
Clinical Associate Professor of Medicine, University of Calgary
Registration opening soon.
Session 4: IBD Clinical Trials - Importance of ongoing pharmacological trials
Tuesday, September 10, 2024 at 5:30 pm
Presenter:
Dr. Remo Panaccione
is a Professor of Medicine at the University of Calgary and the Director of the Inflammatory Bowel Disease (IBD) Clinic and Gastrointestinal Research. He is an internationally recognized expert in inflammatory bowel disease with a special focus on clinical trials for new IBD therapies. Dr. Panaccione's research includes identifying new targets for IBD treatment, and his work has positioned the University of Calgary's IBD Clinical Trials Unit among the top five globally.
Moderator:
Dr. Karen Kroeker
Clinical Associate Professor of Medicine, University of Calgary
Registration opening soon.
Session 1:
Monday, June 17, 2024 at 5:00pm
In this webinar, participants will have the opportunity to learn and ask questions about Celiac disease.
Presenter:
Dr. Justine Turner and Dr. Sander van Zanten
Dr. Justine Turner is a pediatric gastroenterologist and Professor at the University of Alberta. She is medical lead for the Multidisciplinary Pediatric Celiac Disease Clinic at Stollery Children’s Hospital Edmonton. She is a long member of the Professional Advisory Council for the Canadian Celiac Association and Medical Advisor for the Edmonton Chapter of the Canadian Celiac Association.
and
Dr. Veldhuyzen van Zanten has been a member of the University of Alberta GI Division since 2006. He.is an Academic Gastroenterologist who went to medical school and did his Internal Medicine training in Holland. He did his GI training and a Master’s in Clinical Epidemiology at McMaster’s University in Hamilton, Canada from 1986 to 1990. In 1992, he received a PhD in Medicine on the topic of "Clinical Aspects of Helicobacter pylori infection" from the University of Amsterdam.
Moderator:
Dr. Karen Kroeker,
Clinical Associate Professor of Medicine, University of Calgary
Learning Objectives:
- Describe key treatment decision points in the new pathway for management of Celiac disease;
- Explain the benefits that could be achieved through harmonization of lab testing across Alberta, and the impact that treatment algorithms may have on testing;
- Review opportunities for quality improvement that may be achieved via use of the pathway
- Discuss a maximum wait time of < 8weeks for biopsy confirmation of the diagnosis.